Skip to main content

Advertisement

Fig. 5 | Cell & Bioscience

Fig. 5

From: Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

Fig. 5

pNGVL4a-Sig/E7(detox)/HSP70 DNA priming followed by TA-CIN boost generated potent protective anti-tumor effects against subsequent TC-1 tumor challenge. One group of 5 ~ 8 weeks old female C57BL/6 mice (5 mice/group) was vaccinated with 25 μg/mouse of pNGVL4a-Sig/E7(detox)/HSP70 DNA in 50 μl three times. Another group of mice was vaccinated with 25 μg/mouse of TA-CIN protein in 20 μl three times. The third group of mice was vaccinated with 25 μg/dose of pNGVL4a-Sig/E7(detox)/HSP70 DNA in 50 μl twice followed by single 25 μg/mouse of TA-CIN protein in 20 μl. All vaccinations were given via intramuscular injection (leg muscle) with 1-week interval. Seven days after the last vaccination, the mice were injected with 2 × 105 of TC-1 tumor cells subcutaneously. a Schematic illustration of the experiment. b Summary of tumor incidence. c Kaplan–Meier survival analysis of TC-1 tumor-bearing mice

Back to article page